From: A multi-stakeholder approach to the co-production of the research agenda for medicines optimisation
Patient Concerns | PPI rank (n = 7) | Non-PPI rank (n = 25) |
 Is there a shared decision (with patients) about using each medicine? | 1 | 2 |
 How are medication reviews by different healthcare professionals integrated? | 2 | 5 |
 To what extent are patients’ views and experiences considered during medication reviews? | 3a | 1 |
 What are patients’ perspectives and experiences of non-medical prescribers, and does this vary according to different professional groups and different patient groups? | 3b | 10 |
 How can communication relevant to medication reviews be enhanced across and within sectors? | 5 | 3 |
Polypharmacy | PPI rank | Non-PPI rank |
 To what extent should polypharmacy involve patients’ views and preferences in shared decision-making? | 1 | 5 |
 What can patients teach health care professionals about the burden of polypharmacy and coping (or not) mechanisms? | 2 | 11 |
 Which patients should be targeted by polypharmacy medication reviews, where and when? | 3 | 7 |
 What are the key components of a good, person-centred, holistic, polypharmacy medication review? | 4 | 6 |
 If we undertake a polypharmacy medication review well with the right person at the right time, what happens to the patient (i.e. are their outcomes better, does their ‘quality of life’ improve etc.)? | 5 | 2 |
Non-medical Prescribing | PPI rank | Non-PPI rank |
 How can we optimise the contribution of non-medical prescribers to primary care? | 1 | 1 |
 How can we raise patient awareness of these ‘new’ prescribers? | 2 | 10 |
 What is the role of the NMP in medicines reviews (e.g. in specialist areas such as rheumatology and type of NMP e.g. pharmacist, nurse)? | 3a | 6 |
 How can non-medical prescribers optimise medicines use in vulnerable patient populations e.g. drug misusers, individuals with mental illness? | 3b | 13 |
 How is deprescribing, polypharmacy, etc. undertaken by non-medical prescribers? | 5 | 2 |
Deprescribing | PPI rank | Non-PPI rank |
 How can we empower patients to take a more active role in self-management and self-monitoring of multiple long-term conditions, including deprescribing? | 1 | 2 |
 Should all ‘prescribing’ guidelines include recommendations to deprescribe, and if so how? | 2 | 9 |
 How can GPs and non-medical prescribers be assisted in dealing with deprescribing of medicines originally prescribed by hospital consultants? | 3a | 9 |
 Does providing full access to medical records enable more effective collaborative deprescribing decisions? | 3b | 8 |
 How can pharmacological and holistic therapies be merged? E.g. deprescribing of antidepressants. | 3c | 18 |